NEW YORK (AP) — Shares of Vivus Inc. rose and Orexigen Therapeutics Inc. forsaken Friday after a Food and Drug Administration panel wrapped adult dual days of discussions on obesity drugs.
The FDA‘s advisory panel discussed a heart risks of plumpness drugs Wednesday and Thursday as a group continues to guard growth of weight detriment drugs by Vivus, Orexigen, and Arena Pharmaceuticals Inc. The FDA has already deserted any company’s drug claimant once, citing reserve concerns, though a companies are stability to try to win selling approval.
The group is scheduled to make a preference on Vivus’ drug Qnexa by Apr 17 and on Arena’s lorcaserin by Jun 27. A apart advisory row pronounced in Feb that Qnexa should be approved, and a row examination of lorcaserin is scheduled for May 10. Orexigen hopes it can win capitulation for Contrave in 2014.
Analysts...
0 comments
Post a Comment